We are thrilled to announce that our collaborative project "NEUROQUANT" has been awarded funding through the prestigious UK-Switzerland CR&D Round 2 Competition. This international partnership brings together leading expertise from Skope Magnetic Resonance Technologies AG (Switzerland), MR CoilTech Limited (UK), Gold Standard Phantoms (UK), and Hôpitaux universitaires de Genève (Switzerland).
NEUROQUANT will develop a revolutionary neurovascular MR coil that enables quantitative imaging of the entire brain and upper spine, specifically designed to advance Alzheimer's disease research. By combining state-of-the-art field-monitoring technology with innovative calibration phantoms, our solution will significantly improve image quality, stability, and quantitative accuracy at ultra-high field strengths.
This breakthrough technology aims to enhance the detection and quantification of amyloid plaques and other biomarkers, while supporting longitudinal studies critical for disease understanding, drug development, and therapy monitoring.
The 26-month project commences in November 2024, representing a significant step forward in our mission to improve diagnostic capabilities and ultimately contribute to better outcomes for millions affected by Alzheimer's disease worldwide.
*This project is co-funded by Innovate UK and Innosuisse under the UK-Switzerland bilateral research program.*
